| Issue | Title | |
| Vol 2004, No 48 (2004) | Schering AG Agrees to Commercialise Praecis' Plenaxis™ | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | Schering AG to Market Campath® in South East Asia | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Schering and Astex Enter Multi-target Drug Discovery Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Schering-Plough Acquires Rights to Antibodies | Abstract |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | Schering-Plough and Merck & Co. to Develop new Cholesterol Treatment | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Schering-Plough and Novartis: Newcomers to the Combination Market | Abstract |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Schering-Plough in US$14.4 B Acquisition of Organon BioSciences | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 47 (2004) | Schering-Plough Licenses Toyama’s Antibacterial Agent | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Schering-Plough to Distribute Novartis Asthma Product in US | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Schering’s and Novartis’ New Co-Promotion Agreement for PTK/ZK | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 4 (2011) | SciClone Strengthens its Presence in China with NovaMed Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 11 (2009) | Sciele Buys Partner Addrenex | Abstract |
| Taskin Ahmed | ||
| Vol 2022, No 10 (2022) | Seagen Enters into License Agreement with Lava Therapeutics for LAVA-1223 | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2022, No 10 (2022) | Seagen Signs Collaboration and License Agreement with Zai Lab for Tivdak® | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2009, No 12 (2009) | Seasons Greetings from PharmaVentures Ltd | Abstract jpg |
| Clive Goddard | ||
| Vol 2009, No 12 (2009) | Seattle Genetics and Agensys Expand Cancer Collaboration | Abstract |
| Taskin Ahmed | ||
| Vol 2013, No 7 (2013) | Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | Seattle Genetics Boosts Cash Pile with January Deals | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 2 (2018) | Seattle Genetics Strengthens Pipeline with Acquisition of Cascadian for US$614 M | Abstract pdf html |
| Arun Manohar | ||
| Vol 2009, No 5 (2009) | SEC Probes Schering-Plough Trades before Merck Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 82 (2007) | Security | Details jpg |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Seeking the 'Delta' | Details html |
| Fintan Walton | ||
| Vol 2012, No 12 (2012) | Selecta Biosciences Partners with Sanofi to Develop Antigen-Specific Immunotherapies for Allergies | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 31 (2002) | Senetek Enters into Two Agreements in its Core Areas of Erectile Dysfunction and Skin Care | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Sepracor and ACADIA Forge CNS Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | Sepracor Enters into Multiple Deals with Arrow | Abstract pdf html |
| The PharmaDeals Team | ||
| Vol 2007, No 88 (2007) | Sepracor’s Insomnia Drug Enters Europe with GSK Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | Sereno and Genmab Partner Again with a US$215 M Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 49 (2004) | Sereno SA | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 46 (2004) | Serono and InDex in Ulcerative Colitis Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Serono and Nautilus Sign Hormone Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 54 (2004) | Serono and Paratek in MS Partnership | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 76 (2006) | Serono Changes Tack Again and Finds Buyer | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Serono Continues its Deal Making Spree through Collaborations with BioMarin and NovImmune | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Serono Launches Bid to Acquire Genset | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 66 (2005) | Serono Licenses Aurora Kinase Inhibitors from Rigel | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Serono SA | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Serono: Takeover Talk | Abstract |
| Business Review Editor | ||
| Vol 2020, No 2 (2020) | Servier Expands Cellectis UCART19 Collaboration | Abstract html pdf |
| Michelle Liu | ||
| Vol 2011, No 12 (2101) | Servier Options MacroGenics’ Phase I Cancer Immunotherapy | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 100 (2008) | Shionogi Keeps Up with Latest Japanese Pharma Trend | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2008, No 98 (2008) | Shire Acquisition Provides Company with a Market-Ready Drug | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2013, No 4 (2013) | Shire Adds Phase III Ophthalmology Asset to Pipeline with SARcode Bioscience Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 1 (2016) | Shire Aims for Market Leadership in Rare Diseases with US$32 B Baxalta Acquisition | Abstract pdf html |
| Heather Cartwright, Rohit Khera & Jasmine Kalsi | ||
| Vol 2005, No 57 (2005) | Shire and New River: Buying up the Competition | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Shire and Noven in ADHD Deal | Abstract |
| Business Review Editor | ||
| Vol 2012, No 3 (2012) | Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 3 (2012) | Shire Collaborates with arGEN-X to Discover and Develop Antibody Products for Rare Diseases | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 89 (2007) | Shire Divests Non-Essential Products | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 5 (2018) | Shire Divests Oncology Products to Servier | Abstract html pdf |
| Natasha Piper | ||
| Vol 2014, No 7 (2014) | Shire Finally Accepts AbbVie’s Advances with US$54.8 B Deal | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 86 (2007) | Shire Gains Anti-Scarring Product, Juvista® | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Shire Licenses Genetic Disease Therapy to Amicus | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 8 (2014) | Shire Licenses Hunter Syndrome Therapy from ArmaGen Technologies | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 8 (2010) | Shire Licenses Rights to Duchenne Muscular Dystrophy Drug Candidate from Acceleron | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Shire Licenses Sangamo’s Genome-Editing Technology for Haemophilia and Other Monogenic Diseases | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 11 (2015) | Shire Looks to Protect HAE Franchise with US$5.9 B Dyax Acquisition | Abstract PDF html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2013, No 5 (2013) | Shire Partners with Nimbus Discovery to Develop Oral Therapies for Lysosomal Storage Disorders | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 11 (2013) | Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 4 (2012) | Shire Strengthens its Regenerative Medicine Business with Pervasis Therapeutics Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 9 (2009) | Shire Targets More Rare Diseases with Santaris’ LNA Platform | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 7 (2010) | Shire to Acquire Movetis and Expand its Gastrointestinal Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 2 (2009) | Shire to Enter European ADHD Market | Abstract html |
| Taskin Ahmed | ||
| Vol 2011, No 6 (2011) | Shire to Enter Regenerative Medicine Market with Advanced BioHealing Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 2 (2015) | Shire’s Bet on NPS Pharma Pays Off with Natpara® Approval | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 44 (2004) | Shire’s Exit Strategy from Japan Provides Bayer with Exclusive Product Rights | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Shortening the Adoption Curve | Abstract |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Siemens and Dade: A Symptomatic Consolidation | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 9 (2012) | Silence Therapeutics Collaborates with MiReven to Evaluate Delivery of miR-7 Mimetic | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 65 (2005) | Silodosin | Abstract pdf |
| Business Review Editor | ||
| Vol 2025, No 8 (2025) | Sino Biopharmaceutical Expands Oncology Portfolio with US$950.9 M Acquisition of LaNova Medicines | Abstract html pdf |
| Swati Sharan | ||
| Vol 2006, No 78 (2006) | Sirna acquired by Merck for US$1.1 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | SkyePharma in Separate Licensing and Drug Delivery Technology Sharing Agreements | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | SkyePharma License Marketing and Distribution Rights for DepoCyte® to Mundipharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | SkyePharma Licenses Further Solaraze Rights to Shire; Makes Investment in Micap | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | SkyePharma plc | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 66 (2005) | SkyePharma Signs Development and Marketing Agreement with Maruho | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | SkyePharma’s Deal Strategy | Abstract |
| Business Review Editor | ||
| Vol 2019, No 7 (2019) | Skyhawk Signs its First Oncology Deal with Merck | Abstract pdf html |
| Michelle Liu | ||
| Vol 2003, No 35 (2003) | Smith & Nephew and Centerpulse Merge to Form Global Orthopaedics Company | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 12 (2012) | Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 82 (2007) | Smith & Nephew’s Acquisition of Plus Orthopedics Makes it Key Player in Reconstructive Surgery Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 10 (2019) | Sobi Acquires Dova in US$915 M Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 59 (2005) | Solvay Looks to Fournier to Expand Drugs Business | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Solvay Pharmaceuticals Launches Friendly Takeover Bid for Neopharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | Sonus Finds Way Out through Merger with OncoGenex | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2005, No 65 (2005) | Sonus Grants Exclusive Worldwide License to Schering | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Sosei In-Licenses Otsuka’s Urology Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 2 (2010) | Spectrum and TopoTarget in US$350 M Deal for Belinostat | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 4 (2012) | Spectrum Pharmaceuticals Agrees to Acquire Allos Therapeutics After Apaziquone Setback | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 70 (2006) | Spotlight on Influenza - Separating Fact from Fiction in the Fight against Influenza | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 10 (2013) | Stallergenes and DBV Technologies Partner to Develop Birch Pollen Allergy Immunotherapy | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 5 (2012) | Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 9 (2010) | Stem Cells | Abstract jpg |
| Clive Goddard | ||
| Vol 2009, No 10 (2009) | Still Waiting for the Turning Point in Deal Making | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 5 (2009) | Strategic Agreement Between Genzyme and Bayer | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 12 (2101) | Stress | Abstract jpg |
| Clive Goddard | ||
| Vol 2002, No 26 (2002) | Stressgen Licenses Heat Shock Fusion Protein to Roche | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 51 (2004) | Structural GenomiX Acquires Troxatyl® from Shire | Abstract pdf |
| Business Review Editor | ||
| 2201 - 2300 of 2613 Items | << < 18 19 20 21 22 23 24 25 26 27 > >> | |